14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MDCX vs EXYN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over EXYN (EXYN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MDCX carries a Unified Composite Score of 49.2/100 (HOLD) at $1.14 (N/M Forward P/E, 0.0% operating margin), whereas EXYN carries 50.1/100 (HOLD) at $1.56 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While EXYN currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MDCX 49.2/100 HOLD), MDCX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1); meanwhile EXYN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDCX vs EXYN. Trailing 12-month operating profitability (MDCX 0.0% vs EXYN N/A) and valuation multiples (MDCX N/M vs EXYN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MDCX vs EXYN Key Questions & Quantitative Answers
As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) is the stronger overall head-to-head candidate over EXYN (EXYN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MDCX carries a Unified Composite Score of 49.2/100 (HOLD) at $1.14 (N/M Forward P/E, 0.0% operating margin), whereas EXYN carries 50.1/100 (HOLD) at $1.56 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While EXYN currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MDCX 49.2/100 HOLD), MDCX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1); meanwhile EXYN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MDCX leads the Growth & Scale pillar: MDCX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EXYN at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MDCX generates N/A in USD-normalized revenue versus N/A for EXYN. In operating R&D and SG&A reinvestment, MDCX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EXYN.
MDCX and EXYN trade at balanced relative valuation multiples. MDCX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EXYN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDCX (-7446.1% ROE) versus EXYN (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, MDCX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.28β · 118% Vol realized risk). By comparison, EXYN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.90β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.